Sage Therapeutics, Inc. (NASDAQ: SAGE) Builds Dreams of Depression Treatment Successes
Millions of people in North America report major depression concerns Sage Therapeutics drug trials return dramatic data Testing phase targets central nervous system biomolecule receptors Biopharmaceutical company Sage Therapeutics, Inc. (NASDAQ: SAGE) is reporting optimism over recent product testing in its efforts to reduce the debilitating effects of central nervous system disorders such as depression in its varied forms. Company CEO Jeff Jonas told a CNBC interviewer this month that he’s hopeful a pill now known as SAGE-217 may even become as prominently recognized as Prozac in the treatment of major depressive disorder (MDD), or clinical depression (http://nnw.fm/0PMwt). “What we…







